Overview

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Status:
RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the systemic exposure and characterize the plasma pharmacokinetic (PK) profile and assess the safety and tolerability of ARQ-154 foam 0.3%.
Phase:
PHASE1
Details
Lead Sponsor:
Arcutis Biotherapeutics, Inc.